Abstract Details
|
Carmel Armon, MD, FAAN
(Loma Linda University Department of Neurology)
PRESENTER |
Dr. Armon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Inbal - Israeli Government Insurance Company. Dr. Armon has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neurological Sciences. Dr. Armon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Individual attorney offices. Dr. Armon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Israeli Civil Courts as a court-appointed expert. Dr. Armon has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) | Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. |
| No disclosure on file |